Welcome back to another Pharmacy Times Practice Pearls series. In this episode titled, 'Rationale and Timing: The Evolving Role of BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma,' Ryan Haumschild led the conversation about the following question: What are the potential clinical benefits and risks of introducing B-cell maturation antigen (BCMA)-targeted therapies earlier in the treatment continuum?
In this episode, 'BCMA Biology, Mechanisms of Action, and Unmet Needs in Relapsed/Refractory Multiple Myeloma,' the expert oncologists and oncology pharmacists explored the following questions: What is the biological rationale for targeting B-cell maturation antigen (BCMA) in multiple myeloma? What are the different types of BCMA-targeted therapies and what are the Food and Drug Administration (FDA)-approved options? How do the mechanisms of action differ for the 3 different types of BCMA-targeted therapies? What unmet needs in relapsed/refractory multiple myeloma (RRMM) are addressed by BCMA-directed therapies? What are the potential clinical benefits and risks of introducing B-cell maturation antigen (BCMA)-targeted therapies earlier in the treatment continuum?
